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A population of peripheral B cells have been shown to express recombination
activating gene products, RAG-l and RAG-2, which are considered to be involved in
revising the B cell antigen receptor (BCR) in the periphery. BCR engagement has been
reported to tum off RAG expression in peripheral B cells, whereas the same treatment
has an opposite effect in immature B cells in the bone marrow. In contrast to receptor
editing that is involved in the removal of autoreactivity in immature B cells, it has been
shown that secondary V(D)J rearrangement in peripheral B cells, termed receptor
revision, contributes to affinity maturation of antibodies. Here, we show that RAG-2
expression in murine splenic B cells was abrogated by the coligation of BeR with
complement receptors (CD211CD35) much more efficiently than by the engagement of
BCR alone. On the other hand, the same coligation augmented proliferation of anti-
CD40-stimulated B cells. Consistent with these observations, RAG-2 expression was
lower in the draining lymph nodes of the quasi-monoclonal mice when they were
immunized with a high-affinity antigen than with a low-affinity one. These findings
suggest a crucial role for CD211CD35 in directing the conservation or the revision of
BCRs in peripheral B cells.
1. Introduction
Recently, secondary V(D)J rearrangement (V, variable~ D, diversity; J,joining) ofIg
genes has been shown to occur in the spleen or the lymph node (LN) B cells of
immunized mice, as a consequence of increased expression of the V(D)J recombinase,
RAG-l and RAG-2 (1-7). Several human B cell clones have been identified that are
considered to have undergone secondary Y(D)J rearrangement in the periphery, probably
in GC (8,9). BCR engagement of immature B cells in the bone marrow results in the
enhancement of RAG expression, and leads to immune tolerance by editing autoreactive
BCRs, a process termed receptor editing (10). In contrast, RAG expression in peripheral
B cells may not be tolerance-driven because BCR cross-linking has been shown to turn
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off its expression (11,12). Thus, V(D)J rearrangement in peripheral B cells, recently
referred to as receptor revision, is predicted to contribute to the generation of high-affinity
antibodies (Abs) (13,14). Recently, we have demonstrated that L chain rearrangement in
murine LN B cells that occurs in the course of immune responses contributes to the
generation of high-affinity Abs (15), thus suggesting strongly that receptor revision along
with somatic hypermutation is responsible for affinity maturation by diversifying BCR
repertoire in the periphery.
In germinal centers (GCs), B cells that acquired high-affinity BCRs are positively
selected through interaction with follicular dendritic cells (FOC) that bear immune
complexes, thus leading to affinity maturation of Abs (16,17). Murine B cells and FOC
express the complement receptor type 1 (CRl; CD35) and type 2 (CR2; CD21) (18). B
cells with high-affinity BCRs that interact strongly with immune complexes retained on
FOC via their BCR and CD211CD35 have been shown to receive survival signals (19).
On the other hand, it has been reported that RAG expression was induced in murine
spleen B cells by immunization with a low-affinity antigen, but to a lesser extent with a
high-affinity antigen (11). In this context, it appears reasonable if RAG expression is
turned off in B cells that acquired high-affinity BCR, because the high-affinity BCRs
must be conserved for affinity maturation to occur. In the present report, we show that
coligation of BCR with CD21/CD35 leads to abrogation of RAG expression more
efficiently than BCR engagement alone in murine splenic B cells. Based on these
findings, role for CD211CD35 in the regulation of receptor revision is discussed.
2. Materials and methods
2.1. Mice
Male C3H/HeN mice (7-9 weeks of age) were purchased from Japan Charles River
(Kanagawa, Japan).
2.2. Abs and other reagents
Abs and other reagents used in the present work were obtained from the following
sources: F(ab'h fragment of goat anti-mouse IgM antibody (anti-IA.), Organon Teknika
Co. ( Durham, NC); anti-CD21/CD35 mAb (706, rat IgG2b) and a control rat IgG2b
mAb (A95-1), PharMingen (San Diego, CA); anti-mouse CD40 mAb (LB429) Seikagaku
Kogyo (Tokyo, Japan); avidin, and Chicken y-globulin (CGG) (St. Louis, MO). Anti-
ll, 706 and an isotype-matched control Ab of 706 were biotinylated using a biotinylation
kit (American Qualex, San Clemente, CA) (1).
2.3. Cell CuIture
B cells were prepared by treating spleen cells from C3H/HeN mice with anti-Thy 1.2
mAb plus rabbit complement as described previously (20). The B cells (3 x 106/ml)
were cultured with 1 Ilg/ml anti-mouse CD40 mAb and 10 ng/ml mouse recombinant IL-
4 or IL-7 (PeproTech, Princeton, NJ) for 3 days in 1 ml of RPMI-1640 medium
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containing 10% fetal bovine serum (GIBCO, Grand Island, NY), 1 x 10-5 M 2-
mercaptoethanol, 100 Vlml penicillin G and 50 I-tg/ml streptomycin.
2.4. Proliferative response of B cells
B cells (6 x 105) were cultured in quadruplicate with anti-CD40 plus IL-7 as described
above in 0.2 ml of the culture medium for 48 h. Then, the cells were pulsed with 20kBq
of [3Hl-thymidine (TdR)(Amersham Pharmacia Biotech., Tokyo, Japan) for 16 h.
2.5. Assessment of RAG-2 expression by Reverse transcriptase-dependent-PCR(RT-
PCR)
Total RNA was extracted from lx106 cells from cultures or isolated LNs by the RNA Zol
B method, as described (1). The extracted RNA preparations were reverse transcribed
and resultant cDNA was amplified by PCR using following sense and antisense primers
that span an intron; 5'-CACATCCACAAGCAGGAAGTACAC-3' and 5'- GGTTCA-
GGGACATCTCCTACTAAG-3' for RAG-2, and 5'-CCATCACCATCTTCCAGGAG-
3' and 5'-CCTGCTTCACCACCTTCCTTG-3' for GAPDH, respectively. Ig~ was
amplified using sense 5'-ATGGCCAGGCTGGCGTTGTCTC-3' and antisense 5'-
GAGGCGCTGTTCATGTAGCAGTG-3' as reported by Meffre et al. (12). PCR was
performed using the polymerase, AmpliTaq Gold (Perkin Elmer, Foster City, CA) as
reported previously (6). The amplified products were electrophoresed on 7.5%
polyacrylamide gel and visualized by staining with SYBER Green I (FMC BioProducts,
Rockland, ME). The level of the amplified product of RAG-2 was estimated by Southern
blotting using a [32Pl-Iabeled probe, the Pstl-Hinfl 124 bp internal fragment of RAG-2
cDNA as described previously (6,21).
RT-PCR analysis of IL-7Ra expression was done in a similar fashion using
following primers; sense 5'-CGAGTGAAATGCCTAACTC-3'
and antisense 5'-GCGTCCAGTTGCTTTCAC-3' (21).
2.6. Imunization of mice
Mice were immunized in the footpad with an antigen emulsified in complete Freund
adjuvant as described previously (1,2). Popliteallymphnode (LN) cells were examined
for the expression of RAG-2 as described above. Serum antibody titer was assessed as
described (20).
3. Results
3.1. Downregulation of RAG-2 by coligation of CD211CD35
with BCR.
Isolated murine splenic B cells usually expressed a low but significant level of RAG-
2, which varied in each mouse. Culture of the B cells with or without anti-CD40 for 3
days resulted in a complete loss of RAG-2(2l). The RAG-2 expression was, however,
maintained or more frequently augmented when B cells were stimulated with anti-CD40
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in the presence of IL-7. IL-7 alone did not enhance RAG expression as reported
previously (21). IL-4, as well as IL-7 was effective in augmenting RAG expression in
anti-CD40-activated mouse slenic B cells (1,2,7).
To investigate the regulatory role for the complement receptor (CD211CD35) in the
regulation of receptor revision, it was examined how the level of RAG-2 in anti-
CD40/IL-7-stimulated B cells is modulated by engagement of BCR or by coligation of
BCR with CD211CD35. Mouse CD21 and CD35 are isoforms that are encoded by a
single gene, and generated by an alternative splicing (18). 7G6 is a mAb raised against a
C3d-binding site present on both isoforms (18). The coligation of BCR with
CD211CD35 was performed by treating B cells first with anti-I-t and 706, both of which
were biotinylated, followed by the addition of avidin. RAG-2 expression enhanced by
anti-CD40/IL-7-stimulation was partially reduced when either BCR or CD211CD35 alone
were engaged with anti-I-t (5 I-tg/ml) or 706, respectively. Further ligation of these
bound Abs with avidin did not augment the suppression (Fig. lA, lane 2-lane 6). When
anti-I-t was increased to 10 f,tg/ml, RAG-2 expression was inhibited to a greater extent,
but was not diminished totally (Data not shown). Simultaneous addition of anti-f,t and
7G6 did not show additive inhibitory effects (Fig. lA, lane 7). However, very
interestingly, coligation of BCR with CD211CD35 by avidin resulted in a stronger
suppression of RAG-2 expression than the engagement of either BCR or CD211CD35
alone (Fig. lA, lanes 4,6 and 8). These results were reconfirmed by comparing the level
of the RAG-2 transcript among lanes 2, 4 and 8 in Fig. 1A by semi-quantitative RT-PCR
that was performed with varying PCR cycles or with varying dilutions of eDNA. Similar
observations were made in the RAG expression in B cells stimulated with anti-CD40 +
IL-4 (Data not shown).
The coligation-dependent suppression of RAG-2 expression was similarly observed
when BCR were engaged weakly with a lower concentration of anti-f,t (l f,tg/ml). RAG-2
expression was markedly suppressed when BCR and CD211CD35 were coligated while
the engagement of BCR alone showed weak inhibitory effects (Fig. IC, lanes 2, 3, and
6). On the other hand, the coligation-induced suppression was abrogated when 7G6 was
replaced by an isotype-matched control mAb (Fig. IC, lanes 3 and 4), thus indicating that
the coligation of BCR with CD211CD35 but not with other molecules on B cells including
FcyRII may be responsible for the suppression.
We have reported that isolated IgD+ splenic B cells are originally IL-7R-negative, but
a part of the B cells become positive for IL-7R in response to anti-CD40/IL-7 in vitro
(21). Inhibition of the RAG-2 expression by coligation of BCR with CD211CD35 may
not be due to the suppression of IL-7R expression, because expression of IL-7Ru was
not significantly affected by the coligation (Fig. IB). It was confirmed that the y
common chain, another subunit of IL-7R, was constitutively expressed in these B cells
(Data not shown).
Collectively, RAG-2 expression in splenic B cells was more strongly downregulated
by the coligation of BCR with CD211CD35 when the engagement of BCR alone caused
only partial inhibition.
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Fig. 1. (A) Inhibition of RAO-2 expression in anti-CD40/IL-7-stimulated B cells by
coligation of BCR wilh CD2I!CD35. Anti-I.l (F(ab')2 fragment), anti-CD21!CD35 mAb
(706) and its isotype-matched control mAb were used as biotinylated forms. Murine B
cells were cullured with anti-CD40/IL-7 for 3 d. Where indicated, 5 fJ.g/ml anti-fJ., 5
IJ.g/ml 706 and 5IJ.g/mi avidin were added, alone or in combination, to the culture.
RAG-2 expression was assessed on day 3 of the culture by RT-PCR/Souther blotting.
(B) RAG~2 expression was inhibited much more strongly by coligation of BCR with
CD21/CD35 than by engagement or ~CR alone. The expression of RAG~2and IL-7Ra
was compared among lanes 2, 4 and 8 in panel A. (C) RAG-2 expression was inhibited
efficiently by coligation of BCR with CD21/CD35 even when BCR were engaged with a
lower concentration of anti-~l. B cells were stimulated with anti·CD40/IL-7 in the
presence of lor 5 fJ.g/ml anti-IJ.. 5 lJ.g!ml7G6or an isotype-matched control mAb (Co),
and 5IJ.g/mi avidin. All results are represenlatives of five experiments.
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3.2. Enhanced proliferation of splenic B cells by the coligation of CD211CD35 with
BCR.
It has been reported that coligation of CD211CD19 coreceptor with BCR enhances
signal transduction and effectively reduces the affinity threshold for BCR-mediated B cell
activation (18,22,23). Next, it was investigated how the activation status of anti-
CD40/IL-7-stimulated B cells is modulated when RAG expression is suppressed. [3H]_
thymidine uptake was induced in B cells that were stimulated with anti-CD40/IL-7, and
was further was augmented when BCR of the B cells were coligated with CD211CD35
(Fig. 2). On the other hand, anti-!.! plus 7G6 had no enhancing effects when these two
Abs were not coligated with avidin. Avidin itself had no effects on the anti-CD40/IL-7-
induced proliferation (Data not shown). Thus, it is considered that coligation of BCR
with CD211CD35 delivers a stimulatory signal for B cell proliferation concomitant with
an inhibitory signal for RAG expression.
None
+ anti-CD40/lL-7
I+ anti-fAl7G6+ anti-fAIlG6+ avidin
o 10 20 30 40
[3H]-TdR uptake (cpm x 10-3)
50
Fig. 2. Augmentation of proliferative response of anti-CD40/IL-7-stimulated B cells by
coligation of BCR with CD211CD35. B cells (6 x 105) were stimulated with 1 !.!glml
anti-CD40 and 10 ng/ml IL-7 for 48 h, followed by incubation with [3H]-TdR for 16 h.
Biotinylated anti-!.! (1 !.!g/ml) and 7G6 (5 !.!g/ml) with or without avidin (5 !.!g/ml) were
added to the culture as indicated. Data are mean cpm + SD from quadruplicate wells.
Representative data from two experiments.
3.3 A low-affinity Ag induces a higher level of RAG-2 in vivo.
In vitro experiments described above strongly suggest that mutated B cells generated
during GC reaction will conserve their BCR by inhibiting RAG expression if their BCR
and CD211CD35 are coligated strongly with Ag-C3d complexes on FDC. If this is also
the case in vivo, GC B cells with low-affinity BCR for the immunized antigen will
express a higher level of RAG-2 than the high-affinity clones. We attempted to confirm
this assumption using the QM mouse, which is an anti-4-hydroxy-3-nitrophenylacetyl
(NP) IgH-knock-in strain with the genotype VHDJHI7.2.25/JH-, K-/K-, A+/A+ (24).
We selected two NP-related ligands for anti-NP BCR in QM mice. A hapten, 3-nitro-4-
hydroxy-5-iodophenylacetyl (NIP) is a high-affinity ligand that has -11 fold higher
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association constant than that of NP as reported previously (15). On the other hand, we
selected p-nitrophenylacetyl (pNP) as a low-affinity ligand, which showed morc than
-100 fold lower affinity than NIP (Fig. 3A,l5). QM mice were immunized \l.ith either
NIP- or pNP-conjugated chick:en-y-globulin (CGG) in the footpad, and the expression of
RAG-2 in popliteal LN cells was assessed by RT-PeR. RAG-2 expression was not
detected on dayO. An increased level of RAG-2 transcript was observed on day 10 in the
LN of QM mice that were immunizcd with pNP-CGG, whereas RAG-2 expression was
only marginal when immunized with NIP-CGG (Fig. 38). This may not be due to that
QM mice are unresponsivc to NIP-CGG because anti-NP IgM in the serum increased
similarly after immunization with either anti~en (Fig. 3C). Thus, these findings together
with those in in vitro experiments strongly suggest that RAG expression is regulated by
combined signals mediated by BCR and CD21/CD35.
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Fig. 3. RAG-2 expression in QM mice that were immunized with either a high-affinity or
a low-affinity Ag. (A) Structures of a high-affinity hapten (NIP) and a low-affinity
haptcn (pNP). The affinity for anti-NP IgM from QM mice was presented as a relative
association constant where the affinity of NP hapten was defined as 1.0 (association
constanl, - 2 x 106/M). (B) RAG-2 expression and (C) anti-NP IgM response in QM
mice immunized with either pNP-CGG or NIP-CGG. Male QM mice (N = 3) were
immunized with either NIP-CGG or pNP-CGG in lhe footpad. On day 0 and day 10 after
immunization, RAG-2 expression was assessed in pooled JX>pliteal LN cells by RT-PeR
with the varying reaction cycles indicated. Anti-NP IgM levels in fXX>led sera that were
collected from mice immunizcd with NIP-CGG (triangle) or pNP-CGG (circle) on day 0
(open symbol) or day 10 (closed symool) were assayed by ELISA using a plate coated
with NP-BSA and peroxidase-conjugated goat anti-mouse IgM. Data are mean ± SD
from triplicate assays. Representative data from two experimenlc;;.
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V(D)J rearrangement in peripheral B cells, termed receptor revision has been
implicated to contribute to the generation of high-affinity Abs (13,14). Our recent
experiments have shown that this is the case. We have observed that new rearrangement
of f... gene that occurs in the draining LN B cells after immunization contributes to the
generation of high-affinity IgG bearing f... chains (15). Therefore, receptor revision along
with somatic mutation may be involved in affinity maturation of Abs. Using knockin
mice whose RAG-2 expression can be monitored by a green fluorescent protein (GFP)
reporter, it has been suggested that an increase in RAG+ B cells in the spleen after
immunization is largely due to migration of immature-type B cells
(B22010wHSAhigh493+) from the bone marrow (25,26). In contrast to these
observations made in the spleen, we did not observe an increase of immature B cells in
the draining LN after immunization in the foot pad (15), consistent with the fact that only
mature B cells enter LNs (27). A majority of RAG-expressing B cells in the LN were
B220high493-GL-7+, a GC-like phenotype (Our unpublished data). Although further
studies are needed to characterize RAG-expressing B cells in the periphery, these cells are
qualitatively different from immature B cells in the bone marrow, because it has been
reported that BCR engagement results in turning off of RAG expression in the former
(11,12), but in its augmentation in the latter (9,10).
In the present report, we show that CD211C035 may playa crucial role in the
downregulation of RAG expression: The involvement of CD211CD35 is interesting in
the context of B cell selection in GCs. In GCs, centroblasts actively undergo somatic
hypermutations of V regions of Ig genes in the dark zone, and differentiate into
centrocytes with diversified BCR in the light zone (16,17). Centrocytes that interact
strongly with Ag-C3d complexes presented on FOC are positively selected to become
memory or plasma cells, whereas low-affinity or autoreactive clones may be deleted
(16,17). One hypothesis is that receptor revision must be shut off in B cells that acquired
high-affinity BCR, otherwise affinity maturation would be disturbed. This regulatory
mechanism may be operative because our experiments showed that coligation of BCR
with C021/C035 led to turning off of RAG expression. In human tonsil B cells, RAG
expression was abrogated by cross-linking BCRs with anti-K Abs (12). In 3-83 (anti-H-
2Kk) transgenic mice, V(D)J recombination in splenic B cells were induced by
immunization with a low-affinity recombinant antigen, but not with a high-affinity
antigen (11). We made a similar observation using the quasi-monoclonal mouse, who
expresses a site-directed IgH gene specific for NP hapten (24). RAG expression was
much higher in the draining LN B cells when the mice were immunized with p-NP, a
low-affinity analog of NP than with NIP, a high-affinity hapten. Thus, it is suggested
that RAGs in peripheral B cells may be downregulated when the cells acquire high-
affinity BCRs.
On the other hand, the same coligation delivers stimulatory signal(s) for the
proliferation of B cells (Fig. 3). When C021 complexed with CD19 is coligated with
BCR, it has been shown that signals induced through each receptor may synergize and
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provide a stronger stimulus for inducing B cell proliferation (22,23). Therefore,
CD211CD35 is considered to playa critical role in directing the conservation or the
revision of acquired BCRs, thereby supporting affinity maturation.
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